EMA’s PRAC Recommends Additional Zinbryta Restrictions

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency’s pharmacovigilance committee recommended additional restrictions on Biogen’s Zinbryta (daclizumab), after reviewing its effects on the liver.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor